

This week in therapeutics

Indication	Target/marker/pathway	Summary	Licensing status	Publication and contact information
Cancer				
Pancreatic cancer	NEDD8 activating enzyme (NAE)	<i>In vitro</i> and mouse studies suggest NAE inhibitors could help sensitize pancreatic cancers to radiation therapy. In mice with human prostate cancer xenografts, MLN4924 plus radiation inhibited tumor growth better than MLN4924 or radiation alone. Next steps could include testing whether MLN4924 sensitizes other cancers to radiation therapy. Takeda Pharmaceutical Co. Ltd.'s Millennium Pharmaceuticals Inc. subsidiary has MLN4924 in Phase I testing to treat various cancers.	Unpatented; unavailable for licensing	Wei, D. <i>et al. Cancer Res.</i> ; published online Nov. 9, 2011; doi:10.1158/0008-5472.CAN-11-2866 Contact: Yi Sun, University of Michigan, Ann Arbor, Mich. e-mail: sunyi@umich.edu
<p>SciBX 4(46); doi:10.1038/scibx.2011.1293 Published online Dec. 1, 2011</p>				